Climb Bio reports Phase 1 data for CLYM116 showing near-complete APRIL suppression, supports 12-week dosing in IgA nephropathy - CLYM News | RalliesClimb Bio reports Phase 1 data for CLYM116 showing near-complete APRIL suppression, supports 12-week dosing in IgA nephropathy
C
CLYM• Development timeline
- A Phase 2 IgA nephropathy study is ongoing, with initial results expected in H1 2027; a Phase 3 start is planned for 2027.
- Additional Phase 1 updates, including a separate China healthy-volunteer study, are scheduled for presentation in Q4 2026.
Phase 1 data support long-acting dosing
- Climb Bio released initial Phase 1 data for CLYM116, positioning the drug for less frequent dosing in IgA nephropathy.
- The readout showed sustained target suppression with accompanying reductions in disease-related antibodies, supporting a long-acting profile.
- Safety findings were clean in healthy volunteers, with no major tolerability signals flagged in the dataset.
SOFI
•
